Friday, October 30, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64

View original at finance.yahoo.com
JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64 McCormick & Company, Incorporated (NYSE:MKC) is one of the 10 Best Stocks That Beat Earnings Estimates…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Certain AI stocks offer greater upside potential and carry less downside risk than MKC

    60% confidence

  • Projected tax rate of 24% for FY26

    60% confidence

  • McCormick price target lowered to $64 from $67 with Overweight rating maintained

    60% confidence

  • McCormick is not receiving the 'benefit of the doubt' from investors regarding its food deal

    60% confidence

  • Volumes were in line with expectations and anticipates sequential improvement through the year, supported by brand investments, innovation, and distribution gains

    60% confidence

  • FY26 adjusted EPS guidance of $3.05-$3.13 versus $3.09 consensus

    60% confidence

  • The company delivered growth in sales, operating income, and earnings per share, supported by the McCormick de Mexico acquisition and organic growth across both segments, alongside cost discipline that drove margin expansion

    60% confidence

  • Expected revenue growth of 13%-17% for FY26

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com
JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64 — Source | Via News | Finance Via News